FY2024 Earnings Forecast for NMRA Issued By William Blair

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Analysts at William Blair reduced their FY2024 earnings estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($1.63) for the year, down from their prior estimate of ($1.48). The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.48) per share. William Blair also issued estimates for Neumora Therapeutics' Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($1.94) EPS.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.07). During the same period in the prior year, the company posted ($1.14) EPS.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Neumora Therapeutics in a research note on Wednesday. Royal Bank of Canada reiterated an "outperform" rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.67.

Neumora Therapeutics Trading Down 7.3 %

NASDAQ NMRA traded down $0.85 on Friday, reaching $10.84. 956,435 shares of the stock were exchanged, compared to its average volume of 730,514. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00. The firm has a market capitalization of $1.75 billion, a PE ratio of -5.84 and a beta of 3.92. The company's 50-day simple moving average is $13.09 and its two-hundred day simple moving average is $11.41.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Amalgamated Bank boosted its stake in Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company's stock worth $29,000 after buying an additional 2,402 shares during the period. Quarry LP purchased a new stake in shares of Neumora Therapeutics during the second quarter valued at $98,000. SkyOak Wealth LLC purchased a new stake in shares of Neumora Therapeutics during the second quarter valued at $147,000. Principal Financial Group Inc. purchased a new stake in shares of Neumora Therapeutics during the second quarter valued at $166,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Neumora Therapeutics during the third quarter valued at $175,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the transaction, the director now directly owns 20,100 shares of the company's stock, valued at $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $11.78, for a total transaction of $372,742.76. Following the transaction, the chief financial officer now directly owns 154,658 shares of the company's stock, valued at $1,821,871.24. The trade was a 16.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,538 shares of company stock worth $1,390,513. Insiders own 26.40% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.